Ginkgo Bioworks Joins STRM.BIO-Led Consortium to Advance In Vivo CAR-T Therapies

Reuters

2025/12/03

<a href="https://laohu8.com/S/DNA.WS">Ginkgo Bioworks</a> Joins STRM.BIO-Led Consortium to Advance In Vivo CAR-T Therapies

Ginkgo Bioworks Holdings Inc. has entered into a collaboration with STRM.BIO, the University of British Columbia (UBC), and Advanced Bioprocess Services (ABS) to advance the development of in vivo CAR-T therapeutics. This partnership is supported by an ARPA-H contract awarded to STRM.BIO under the EMBODY program, with up to $8.4 million in funding for the first phase. Ginkgo Bioworks will contribute its expertise in RNA construct design and immune cell engineering to help develop STRM.BIO's megakaryocyte-derived extracellular vesicle delivery platform, aiming to create innovative, non-viral approaches to cell and gene therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE37683) on December 03, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2588075046"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588075046\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588075046?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588075046","market":"nz","top_or_hot":-1,"title":"Ginkgo Bioworks Joins STRM.BIO-Led Consortium to Advance In Vivo CAR-T Therapies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DNA.WS\">Ginkgo Bioworks</a> Joins STRM.BIO-Led Consortium to Advance In Vivo CAR-T Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks Holdings Inc.</a> has entered into a collaboration with STRM.BIO, the University of British Columbia (UBC), and Advanced Bioprocess Services (ABS) to advance the development of in vivo CAR-T therapeutics. This partnership is supported by an ARPA-H contract awarded to STRM.BIO under the EMBODY program, with up to $8.4 million in funding for the first phase. Ginkgo Bioworks will contribute its expertise in RNA construct design and immune cell engineering to help develop STRM.BIO's megakaryocyte-derived extracellular vesicle delivery platform, aiming to create innovative, non-viral approaches to cell and gene therapy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/DNABW\">Ginkgo Bioworks Holdings Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: NE37683) on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ginkgo Bioworks Joins STRM.BIO-Led Consortium to Advance In Vivo CAR-T Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGinkgo Bioworks Joins STRM.BIO-Led Consortium to Advance In Vivo CAR-T Therapies\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-03 21:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DNA.WS\">Ginkgo Bioworks</a> Joins STRM.BIO-Led Consortium to Advance In Vivo CAR-T Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks Holdings Inc.</a> has entered into a collaboration with STRM.BIO, the University of British Columbia (UBC), and Advanced Bioprocess Services (ABS) to advance the development of in vivo CAR-T therapeutics. This partnership is supported by an ARPA-H contract awarded to STRM.BIO under the EMBODY program, with up to $8.4 million in funding for the first phase. Ginkgo Bioworks will contribute its expertise in RNA construct design and immune cell engineering to help develop STRM.BIO's megakaryocyte-derived extracellular vesicle delivery platform, aiming to create innovative, non-viral approaches to cell and gene therapy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/DNABW\">Ginkgo Bioworks Holdings Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: NE37683) on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科學工具和服務","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL103sHN:1","article_id":"2588075046","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588075046","pubTimestamp":1764766884,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ginkgo Bioworks Holdings Inc. has entered into a collaboration with STRM.BIO, the University of British Columbia , and Advanced Bioprocess Services  to advance the development of in vivo CAR-T therapeutics. This partnership is supported by an ARPA-H contract awarded to STRM.BIO under the EMBODY program, with up to $8.4 million in funding for the first phase. Ginkgo Bioworks will contribute its expertise in RNA construct design and immune cell engineering to help develop STRM.BIO's megakaryocyte-derived extracellular vesicle delivery platform, aiming to create innovative, non-viral approaches to cell and gene therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to gene","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","DNA":"Ginkgo Bioworks Holdings Inc.","BK4139":"生物科技","BK4109":"特种化学制品"},"translate_title":"Ginkgo Bioworks加入STRM.BIO领导的联盟，推进体内CAR-T疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNA":0.9},"content_text":"Ginkgo Bioworks Joins STRM.BIO-Led Consortium to Advance In Vivo CAR-T Therapies\n    \n\nGinkgo Bioworks Holdings Inc. has entered into a collaboration with STRM.BIO, the University of British Columbia (UBC), and Advanced Bioprocess Services (ABS) to advance the development of in vivo CAR-T therapeutics. This partnership is supported by an ARPA-H contract awarded to STRM.BIO under the EMBODY program, with up to $8.4 million in funding for the first phase. Ginkgo Bioworks will contribute its expertise in RNA construct design and immune cell engineering to help develop STRM.BIO's megakaryocyte-derived extracellular vesicle delivery platform, aiming to create innovative, non-viral approaches to cell and gene therapy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE37683) on December 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}